Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antimetabolite withdrawal versus maintenance during hospitalized complicated urinary tract infection in kidney transplant recipients
ACTRN12624001408572Phase 4Recruiting
- Sponsor
- Charles University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil and mycophenolate sodium in complicated urinary tract infection (cUTI) (2 arms), sponsored by Charles University. Primary endpoint: Clinical cure and microbiological eradication (overall treatment success). Started Jun 2025; status: recruiting.
02
Drugs
mycophenolate mofetilmycophenolate sodium
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on ACTRN12624001408572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001408572.